ContraVir stock: buy or sell?

CTRV stock price: $2.93 -3.30% At close on July 25th, 2019

Updated on:
July 25th, 2019

0

After sliding a frightening -5.61% on Jul/24, ContraVir Pharmaceuticals closed on July 25th at $2.93 and dropped a horrible -3.30%. With July 25th it's been 3 sliding days in a row, loosing $-0.65 (-18.26%).

ContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections.

Should I buy ContraVir stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, ContraVir stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean CTRV will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is ContraVir stock a buy?

Financial institutions and banks post stock ratings everyday. At Stocks2.com, we found 1 rating published for CTRV stock in the last month.

Is CTRV a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-3-20Maxim GroupBuyHold

ContraVir stock analysis

Daily outlook

After sliding a frightening -5.61% on Jul/24, ContraVir Pharmaceuticals closed on July 25th at $2.93 and dropped a horrible -3.30%.

After sliding a frightening -5.61% on July/24, ContraVir Pharmaceuticals closed on July 25th at $2.93 and dropped a horrible -3.30%. CTRV marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $4.45 would break this short term down trend and open possibilities for reversing this situation. Since last April when CTRV stock price broke down the SMA50d line, it slid $-14.50 per share (-83.19%).

CTRV stock chart (daily)

Weekly outlook

Shares of ContraVir Pharmaceuticals closed this week at $2.93 and plummed a hair-raising -17.70%. By mid June CTRV rocketed an amazing 10.24% in just one week.

Since price and 10-weeks moving average lines crossed down by mid June, CTRV fell $-5.96 per share (-67.04%).

CTRV stock chart (weekly)

ContraVir stock price history

ContraVir IPO was on February 20th, 2014 at $840.00 per share1. Since then, CTRV stock sliced a -99.70%, with a yearly average of -19.90%.

1: Adjusted price after possible price splits or reverse-splits.

ContraVir stock historical price chart

CTRV stock reached 52-week highs at $121.10, and all-time highs 2015-10-05 with a price of 3516.8.

ContraVir stock price target

Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' CTRV stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not detected any price prediction for ContraVir Pharmaceuticals stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

After posting its last earnings report on November, ContraVir . Unfortunately, reported EPS is not yet available in our database.
CTRV earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise
2017-Q1-n/a-0.12n/a
2017-Q2-n/a0.03n/a
2017-Q32017-10-27-0.07-0.08n/a
2017-Q42018-04-03n/an/an/a
2018-Q12018-05-15n/a-0.03n/a
2018-Q22018-08-14n/a-0.38n/a
2018-Q32018-11-14n/a-0.9n/a
2018-Q4-n/an/an/a
2019-Q1-n/an/an/a
2019-Q2-n/an/an/a

Annual financial results

Compared to , last anual revenues report draw of to million dollars. , its profit margin (compared to revenues) to , that is million.

CTRV annual Sales and Income evolution
YearSalesYoYIncome/(margin)YoY

Quarterly financial results

Reported quarter earnings marked $-0.16 M with a profit margin of . Profit margin stayed steady a 0.00% compared to previous quarter when profit margin was inf%. When comparing turnover to same quarter last year, ContraVir Pharmaceuticals sales marked a neutral move and stayed constant a nan%. Looking back to recent quarterly results, ContraVir posted 2 positive quarters in a row.
CTRV quarterly Sales and Income evolution
QuarterSales1QoQ2Income1/(margin)QoQ2

ContraVir ownership

When you are planning to buy shares of a company, it's worth to overview its ownership structure.

ContraVir Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a of all shares.

For a better context understanding, the following table shows ownership data compared to other related companies:

CTRV
Market cap$0.0 M
Total shares0.0 M
Float shares0.0 M
  - Institutional holdings (%)0.0%
  - Insider holdings (%)0.0%
Shares in short selling0.0%

ContraVir summary

Thursday, July 25th, 2019
Open$3.03
Close$2.93
Day range$2.80 - $3.15
Previous close$3.03
Session gain-3.30%
Average true range$0.34
50d mov avg$5.83
100d mov avg$10.36
200d mov avg$21.15
Daily patternlb06a
Weekly pattern lb06a

ContraVir performance

Performance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. In the following table, we compare ContraVir performance to :
Stock3m6m12m
CTRVContraVir Pharmac...-61.95%-87.24%-95.40%

ContraVir competitors

Unfortunately, we could not find any public company that could be defined as ContraVir Pharmaceuticals competitor. This doesn't mean ContraVir Pharmaceuticals does not have any competitor in the market, it's just we could not detected it.